Alwin Capital

Bio-Link is a drug development company established in 2001 and headquartered in Shanghai, China. It specializes in providing bioprocessing solutions for the life science industry, focusing on the development and manufacturing of essential process equipment and consumables. These products are utilized in the production of vaccines, antibody drugs, cell therapy, gene therapy, and other biologics. Bio-Link's offerings encompass upstream cell culture, disposable dispensing reservoirs, downstream chromatography, ultrafiltration, and filtration, along with process development services. The company aims to deliver high-quality and innovative solutions that enhance the efficiency, safety, and competitiveness of the biopharmaceutical supply chain. Additionally, there are indications that Bio-Link may explore wearable technology aimed at elderly care.

Sigma Squares Tech focuses on developing automated manufacturing systems and industrial automation solutions. The company specializes in computer vision technologies and offers cloud-based platforms that analyze significant volumes of industrial data during the manufacturing process. By providing integrated analytical and control solutions, Sigma Squares Tech aims to enhance the efficiency and intelligence of small and medium-sized manufacturing companies.

ICE Bioscience Inc. is a contract research organization based in Beijing, China, specializing in preclinical research solutions for electrophysiology and early drug discovery services. Founded in 2010, the company focuses on the development of ion channel-related pharmaceuticals, particularly targeting the neuronal and cardiovascular systems. ICE Bioscience offers a range of services, including ion channel profiling, cardiac safety panels, brain slice screening, and various molecular biology applications. The company has established proprietary ion channel cell lines for both voltage-gated and ligand-gated channels. Additionally, it maintains a diverse platform for target-based panel screening, supporting drug discovery across multiple therapeutic areas such as immunology, oncology, and CNS diseases. ICE Bioscience is committed to enhancing the drug discovery process through effective communication and flexible collaboration models, aiming to identify and validate drug targets and streamline the progression from compound screening to preclinical candidate selection.

Immupeutics Medical Technology Co., Ltd. is a biomedical research company focused on the development of tumor immunotherapy. The firm specializes in creating immune cell therapy drugs aimed at treating various types of tumors and is committed to advancing companion diagnostic technology and immunological multi-omics technology. Through its research and development efforts, Immupeutics seeks to deliver innovative immune cell therapies and integrated treatment methods that enhance patient outcomes in cancer care.

Sonosemi Medical is a provider of medical devices that specializes in the development of pan-vascular active interventional products, diagnosis, and treatment solutions.

ICE Bioscience Inc. is a contract research organization based in Beijing, China, specializing in preclinical research solutions for electrophysiology and early drug discovery services. Founded in 2010, the company focuses on the development of ion channel-related pharmaceuticals, particularly targeting the neuronal and cardiovascular systems. ICE Bioscience offers a range of services, including ion channel profiling, cardiac safety panels, brain slice screening, and various molecular biology applications. The company has established proprietary ion channel cell lines for both voltage-gated and ligand-gated channels. Additionally, it maintains a diverse platform for target-based panel screening, supporting drug discovery across multiple therapeutic areas such as immunology, oncology, and CNS diseases. ICE Bioscience is committed to enhancing the drug discovery process through effective communication and flexible collaboration models, aiming to identify and validate drug targets and streamline the progression from compound screening to preclinical candidate selection.

Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic diseases, and cancer. Utilizing advanced gene editing and genomic technologies, the company works on creating programmable medicine that enhances treatment options for patients. By leveraging these cutting-edge techniques, Reforgene Medicine strives to improve patient outcomes and provide effective solutions for complex health challenges.

Primont is a researcher and producer of surgical instruments and equipment. They offer medically absorbable synthetic sutures, absorbable knot free sutures, non-absorbable surgical sutures, and non absorbable self sealing surgical sutures.

Neukio Biotherapeutics specializes in developing allogenic immune cell therapies for cancer treatment. The company is dedicated to the research, development, and industrialization of immune cell drugs, particularly through its innovative iPSC-CAR-NK technology. By combining in-house innovation with collaborations with leading partners, Neukio aims to create effective therapeutic solutions for cancer patients globally. Through its efforts, the company seeks to advance the commercialization of these novel treatments, ensuring they are accessible to oncology providers and ultimately improving patient outcomes.

Aibo Medical Robot was established in Shenzhen in June 2020, focusing on the vascular interventional surgery robot market. It is reported that behind this "new" company is the accumulation of years of scientific research and technology - that is , the nearly 30 years of research and development accumulation of the founding team.

Rotex Tech is a technology company specializing in electronic tattoos that cater to healthcare, fitness, and human-computer interaction (HCI). The company develops bioelectric flexible sensor technology, creating ultra-thin and flexible electronic tattoos that adhere to skin and other soft surfaces. This innovative technology enhances the functionality of medical wearables and therapeutic products, offering improved monitoring and data collection capabilities for users.

Zhenzhi Yixue Keji is a tumor immunotherapy technology developer.

Sanegene Bio is engaged in the development of RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. The company’s RNAi drug discovery platform focuses on effectively knocking down disease-causing genes, utilizing advanced RNA technology to ensure specific delivery of multiple RNA drugs. This innovative approach allows for targeted treatment of patients suffering from a range of conditions, including cardiovascular and metabolic diseases, immunology-related diseases, infectious diseases, and disorders affecting the central nervous system and eyes. Through its comprehensive RNAi portfolio, Sanegene Bio seeks to provide effective therapeutic solutions for challenging health issues.

Meibai bio focuses on the R&D, production & sales of biological scaffold material for maxillofacial tissue regeneration for medical and medical plastic and cosmetic clinical needs.

EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Rosenbot provides medical robot technology and uses technological innovation to promote the reform of medical models. It is committed to creating a new generation of orthopedic surgery robot systems with intelligent fracture reduction functions, it is the first in the world to realize advanced technologies such as intraoperative real-time 3D navigation, assisted fracture reduction operation, automatic operation planning, etc. The intelligent surgical operation of the whole operation process meets the urgent needs of clinical treatment.

NeoCura is a biotechnology company based in Shenzhen, China, founded in 2017. It specializes in developing artificial intelligence-based platforms and diagnostic tests aimed at improving cancer treatment and diagnosis. The company's key offerings include NeoCura AI ALPINE, which predicts tumor neoantigen candidates; NeoCura AI EVEREST, designed for validating these neoantigens to enhance patient outcomes; NeoCura TP, an intelligent companion diagnostics tool that forecasts treatment options for immunotherapy; and NeoCura Ag, an AI-enabled immunotherapy that targets patient-specific neoantigens. Additionally, NeoCura provides diagnostic and medical laboratory services, leveraging AI to collect and analyze molecular biology and clinical data for better decision-making by healthcare professionals.

Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic diseases, and cancer. Utilizing advanced gene editing and genomic technologies, the company works on creating programmable medicine that enhances treatment options for patients. By leveraging these cutting-edge techniques, Reforgene Medicine strives to improve patient outcomes and provide effective solutions for complex health challenges.

EdiGene Inc. is a biotechnology company based in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts. Founded in 2015, EdiGene specializes in the development of advanced genome editing technologies aimed at addressing various genetic diseases and cancer. The company focuses on both ex vivo and in vivo gene-editing therapies, utilizing proprietary platforms for modifying genetic information in human cells. Their innovative approaches include gene knockout, knock-in, and targeted mutations, which facilitate the creation of safer and more effective gene therapies. EdiGene also supports pharmaceutical research by providing high-throughput genome screening and drug target analysis, enhancing drug discovery efforts in the industry. Through its commitment to translating genome editing into therapeutics, EdiGene aims to improve human health outcomes and advance scientific research.

Xbiome Co. Ltd., established in 2017 and headquartered in Shenzhen, China, is an AI-based microbiome drug development company. It specializes in the analysis of patient and donor intestinal flora using artificial intelligence to accelerate the development of effective pharmaceuticals for microecological intestinal disorders. Xbiome's products focus on micro-ecological treatment, aiming to manage the gut health of a vast population.